IGC Pharma
35 hedge funds and large institutions have $1.14M invested in IGC Pharma in 2026 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 4 closing their positions.
175% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 4
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
17% more funds holding
Funds holding: 30 → 35 (+5)
0.82% less ownership
Funds ownership: 5.2% → 4.39% (-0.82%)
16% less capital invested
Capital invested by funds: $1.36M → $1.14M (-$220K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$50.8K |
| 2 |
VF
Virtu Financial
New York
|
+$6.45K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$6.2K |
| 4 |
Morgan Stanley
New York
|
+$4.83K |
| 5 |
HighTower Advisors
Chicago,
Illinois
|
+$2.77K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$121K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$78.1K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$8.98K |
| 4 |
DP
Dearborn Partners
Chicago,
Illinois
|
-$6.94K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$3.27K |
IGC Hedge Fund Activity: Q1 2026 in Review
35 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q1 2026, worth a combined $1.14M — down 16% from $1.36M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new IGC positions and 4 closed out — a net gain of 7 holders — while 6 added to existing stakes and 5 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $50.8K. The largest seller was Renaissance Technologies, cutting an estimated $121K.
- 35 institutional investors held IGC Pharma (IGC) as of Q1 2026, up from 30 in Q4 2025.
- Funds reported $1.14M of IGC Pharma stock for Q1 2026, down 16% quarter-over-quarter.
- 11 funds opened new IGC Pharma positions in Q1 2026 and 4 closed out, a net change of +7 holders.
- The largest IGC Pharma buyer in Q1 2026 was Geode Capital Management, an estimated $50.8K added.
- The largest IGC Pharma seller in Q1 2026 was Renaissance Technologies, an estimated $121K sold.
Based on aggregated 13F filings for Q1 2026.